Selective androgen receptor degrader (SARD) ligands and methods of use thereof

A method of treating an androgen receptor dependent disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor degrader (SARD) compound represented by the structure of formula I

• wherein
• T is OH, OR, OCOR, CH3, —NHCOCH3, or NHCOR;
• R1 is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;
• or T and R1 form a 3-8 carbocyclic or heterocyclic ring;
• Y is H, CF3, F, I, Br, Cl, CN, or C(R)3;
• Z is H, NO2, CN, halide, COOH, COR, NHCOR, CONHR,
• or Y and Z form a 5 to 8 membered fused ring;
• X is CH or N;
• R is H, alkyl, alkenyl, haloalkyl, alcohol, CH2CH2OH, CF3, CH2Cl, CH2CH2Cl, aryl, F, Cl, Br, I, or OH;
• A is R2 or R3;
• R2 is a five or six-membered saturated or unsaturated ring having at least one nitrogen atom and 0, 1, or 2 double bonds, optionally substituted with at least one of Q1, Q2, Q3 and Q4, each independently selected from hydrogen, keto, substituted or unsubstituted linear or branched alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, haloalkyl, CF3, substituted or unsubstituted aryl, substituted or unsubstituted phenyl, F, Cl, Br, I, CN, NO2, hydroxyl, alkoxy, OR, benzyl, NCS, maleimide, NHCOOR, N(R)2, NHCOR, CONHR, COOR or COR;
• R3 is halide, N3, OR4, CF3, COR4, COCl, COOCOR4, COOR4, OCOR4, OCONHR4, NHCOOR4, NHCONHR4, OCOOR4, CN, CONH2, CONH(R4), CON(R4)2, SR4, SO2R4, SOR4 SO3H, SO2NH2, SO2NH(R4), SO2N(R4)2, NH2, CO(N-heterocycle), NO2, cyanate, isocyanate, thiocyanate, isothiocyanate, mesylate, tosylate, triflate, PO(OH)2 or OPO(OH)2;
• and
• R4 is H, alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl groups are optionally substituted;
• or its optical isomer or a racemic mixture thereof, pharmaceutically acceptable salt, pharmaceutical product, or any combination thereof.